This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
The Zacks Analyst Blog Highlights Pfizer/BioNTech, Moderna and Novavax
by Zacks Equity Research
Pfizer/BioNTech, Moderna and Novavax are included in this Analyst Blog.
Novavax (NVAX) COVID Jab Aids Growth, Overdependence a Challenge (revised)
by Zacks Equity Research
Despite being one of the few authorized COVID-19 vaccine makers in the United States, Novavax's (NVAX) vaccine struggles for market share.
Bristol-Myers (BMY) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
Investors are likely to focus on the demand for Eliquis and Opdivo, along with an incremental contribution from newer drugs, when Bristol-Myers (BMY) reports Q4 results.
FDA Panel Endorses Simplification of COVID-19 Vaccine Strategy
by Zacks Equity Research
An FDA advisory committee unanimously votes in favor of using the same COVID-19 vaccine strain composition for primary series and booster doses.
Is a Beat on the Cards for Novo Nordisk (NVO) in Q4 Earnings?
by Zacks Equity Research
Novo Nordisk's (NVO) top line is likely to have been driven by sales of its Diabetes and Obesity Care products in the fourth quarter of 2022.
Merck (MRK) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
by Zacks Equity Research
Merck (MRK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Can Pfizer (PFE) Beat Expectations This Earnings Season?
by Zacks Equity Research
Higher alliance revenues from Eliquis, higher sales of Prevnar vaccines and drugs like Vyndaqel/Vyndamax are likely to have contributed to Pfizer's (PFE) sales growth in Q4.
Novavax (NVAX) COVID Jab Aids Growth, Overdependence A Woe
by Zacks Equity Research
Despite being one of the few authorized COVID-19 vaccine makers in the United States, Novavax's (NVAX) vaccine struggles for market share.
Pfizer (PFE) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Pfizer (PFE) closed at $45.07, marking a +0.81% move from the previous day.
Should Invesco Dynamic Large Cap Value ETF (PWV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for PWV
Gilead (GILD) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports its fourth-quarter 2022 results.
Pfizer (PFE) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
by Zacks Equity Research
Pfizer (PFE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Johnson & Johnson (JNJ) Q4 Earnings Top Estimates
by Zacks Equity Research
Johnson & Johnson (JNJ) delivered earnings and revenue surprises of 5.86% and 0.22%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Concert (CNCE) Stock Up 17% Last Week on Sun Pharma Buyout Offer
by Zacks Equity Research
Concert Pharmaceuticals (CNCE) enters into a definitive agreement to be acquired by India-based Sun Pharmaceutical for $576 million. Stock up 17% in the previous week.
Pfizer (PFE) Stock Moves -0.09%: What You Should Know
by Zacks Equity Research
In the latest trading session, Pfizer (PFE) closed at $44.96, marking a -0.09% move from the previous day.
Novavax (NVAX) Gets Nod for COVID-19 Booster Jab in South Korea
by Zacks Equity Research
Novavax's (NVAX) COVID-19 vaccine gets approval in South Korea as a booster dose in adults 18 years and older.
The Zacks Analyst Blog Highlights Pfizer, Abbott Laboratories, Union Pacific Corporation, Citigroup and Intuitive Surgical.
by Zacks Equity Research
Pfizer, Abbott Laboratories, Union Pacific Corporation, Citigroup and Intuitive Surgical are part of the Zacks top Analyst Blog.
J&J (JNJ) Discontinues HIV Vaccine Phase III Mosaico Study
by Zacks Equity Research
J&J (JNJ) discontinues phase III study on its investigational HIV vaccine regimen, which shows that the candidate lacks efficacy in preventing HIV.
Top Analyst Reports for Pfizer, Abbott Laboratories & Union Pacific
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Pfizer Inc. (PFE), Abbott Laboratories (ABT) and Union Pacific Corporation (UNP).
Moderna (MRNA) Up on Upbeat Data From Phase III Study on RSV Jab
by Zacks Equity Research
Data from a late-stage study showed that Moderna's (MRNA) RSV vaccine was 83.7% effective at preventing at least two symptoms in adults aged 60 and older.
3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income
by Zacks Equity Research
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Should You Invest in the Invesco Dynamic Pharmaceuticals ETF (PJP)?
by Zacks Equity Research
Sector ETF report for PJP
Is Invesco Dynamic Large Cap Value ETF (PWV) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PWV